FIORINO, GIONATA
 Distribuzione geografica
Continente #
NA - Nord America 983
EU - Europa 811
AS - Asia 180
SA - Sud America 3
OC - Oceania 1
Totale 1.978
Nazione #
US - Stati Uniti d'America 983
SE - Svezia 317
IE - Irlanda 246
CN - Cina 138
DE - Germania 62
UA - Ucraina 58
GB - Regno Unito 48
SG - Singapore 41
IT - Italia 27
FR - Francia 20
FI - Finlandia 18
BE - Belgio 8
CH - Svizzera 3
BR - Brasile 2
AR - Argentina 1
AT - Austria 1
HR - Croazia 1
JP - Giappone 1
NL - Olanda 1
NZ - Nuova Zelanda 1
RU - Federazione Russa 1
Totale 1.978
Città #
Chandler 289
Dublin 246
Nyköping 136
Jacksonville 128
Ashburn 93
Beijing 66
Dearborn 45
Lancaster 39
Princeton 38
Medford 36
Cambridge 35
Des Moines 31
Boardman 27
Singapore 24
Ann Arbor 17
Jinan 13
Shenyang 13
Los Angeles 12
San Mateo 9
Brussels 8
Tianjin 8
Helsinki 7
Pozzuolo Martesana 6
Wilmington 6
Hebei 5
Washington 5
Zhengzhou 5
Bremen 4
Messina 4
Taizhou 4
Woodbridge 4
Fuzhou 3
Guangzhou 3
Lanzhou 3
Nanchang 3
Changsha 2
Haikou 2
Hangzhou 2
Houston 2
Milan 2
Nanjing 2
Reggio Calabria 2
Rome 2
Tappahannock 2
Venaria Reale 2
Zurich 2
Adliswil 1
Amsterdam 1
Bitonto 1
Brighton 1
Bromsgrove 1
Brooklyn 1
Carini 1
Catania 1
Chicago 1
Jiaxing 1
Leicester 1
Meda 1
Mountain View 1
Munich 1
Ningbo 1
Norwalk 1
Santa Clara 1
Stockholm 1
Taiyuan 1
Trecastagni 1
Urbana 1
Vienna 1
Zagreb 1
Totale 1.420
Nome #
Late-onset Crohn's disease: a comparison of disease behaviour and therapy with younger adult patients: the Italian Group for the Study of Inflammatory Bowel Disease 'AGED' study 75
Response evaluation and safety of thiopurines in the treatment of inflammatory bowel diseases (IBD): safety and response evaluation. 71
Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: a prospective study. 66
Different Segmental Transit Time (TT) Through the Small Bowel May Affect Wireless Capsule (WC) Endoscopy 65
A Prospective Comparison Between Computerized Tomography (CT) and Magnetic Resonance (MR) in Ileo-Colonic Crohn's Disease: A Single-Center Experience. 63
Emerging biologics in the treatment of inflammatory bowel disease: what is around the corner? 60
H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biologics. 60
Balanced Propofol Sedation (BPS) Administered by Non-Anesthesiologists vs Midazolam Alone for Endoscopic Procedure in Patients With IBD: A Single Center Open-Label Trial 58
Review article: anti-fibrotic agents for the treatment of Crohn's disease - lessons learnt from other diseases. 57
Adalimumab in ulcerative colitis: hypes and hopes 57
Acute Severe Colitis: Infliximab and/or Cyclosporine? 56
Familial aggregation in inflammatory bowel disease: Is it genes or environment? 56
Anti-TNF's for postoperative recurrence in Crohn's disease: the if's and how's. 54
Anti-TNF Therapy in Inflammatory Bowel Diseases 54
Heat shock protein 47 is a new candidate molecule as anti-fibrotic treatment of Crohn's disease: authors' reply 54
The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy 54
Influenza A (H1N1)v infection in patients with inflammatory bowel disease: a case series. 53
Leukocyte traffic control: a novel therapeutic strategy for inflammatory bowel disease 52
A prospective comparison between 1.5T magnetic resonance and 3T magnetic resonance in ileo-colonic Crohn’s disease: a single center experience. 52
Narrow-band imaging endoscopy to assess mucosal angiogenesis in inflammatory bowel disease: a pilot study. 51
Postoperative recurrence of Crohn's disease and videocapsule endoscopy: it is necessary to leave no stone unturned. 51
Infliximab Inhibits Mucosal Pathological Angiogenesis in Crohn's Disease 50
Review article: anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease. 49
Safety of a (H1N1)V Vaccine in patients with inflammatory bowel disease treated with immunomodulators and biologicals 47
The bacterial sensor Triggering Receptor Expressed on Myeloid cells 2 (TREM-2) is a crucial pathogenic mediator in inflammatory bowel disease (IBD) 47
Infliximab therapy inhibits inflammation-induced angiogenesis in the mucosa of patients with Crohn's disease. 46
Biological Therapy for Ulcerative Colitis: what is after Anti-TNF. 41
A prospective comparison between CT enterography and MR enterography (MRE) in ileo-colonic Crohn’s disease: a single-center experience. 38
Risk of postoperative recurrence and postoperative management of Crohn's disease. 37
Adalimumab in Crohn's Disease: Tips and Tricks After 5 Years of Clinical Experience 37
null 37
The efficacy of shortening the dosing interval to once every six weeks in Crohn's patients losing response to maintenance dose of infliximab. 35
Videocapsule Endoscopy in Portal Hypertension 35
Mucosal healing in Ulcerative Colitis: Where do we Stand? 35
MRI in Crohn's disease-current and future clinical applications. 35
null 31
Review article: Causative factors and the clinical management of patients with Crohn's disease who lose response to anti-TNF-α therapy. 30
Dual Targeted Therapy: a possible option for the management of refractory Inflammatory Bowel Disease 27
null 27
New drug delivery systems in inflammatory bowel disease: MMX and taylored delivery to the gut. 27
Use of biosimilars in inflammatory bowel disease: Statements of the Italian Group for Inflammatory Bowel Disease. 26
null 26
Prevalence, Pathogenesis and Management of Anemia in Inflammatory Bowel Disease: An IG-IBD Multicenter, Prospective, and Observational Study 16
Comparison of two strategies for the management of postoperative recurrence in Crohn's disease patients with one clinical risk factor: A multicentre IG-IBD study 13
Pragmatic trial design to compare real-world effectiveness of different treatments for inflammatory bowel diseases: the PRACTICE-IBD European consensus 1
Totale 2.012
Categoria #
all - tutte 8.140
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8.140


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020229 0 0 0 0 3 50 39 31 2 47 52 5
2020/2021292 35 0 74 31 10 34 1 3 1 41 33 29
2021/2022246 1 20 3 12 5 1 8 8 1 36 54 97
2022/2023826 73 71 46 109 50 81 18 34 321 10 9 4
2023/2024200 14 29 8 51 20 31 4 13 2 21 0 7
2024/202543 7 6 27 3 0 0 0 0 0 0 0 0
Totale 2.012